Celentano A, Galderisi M, Tammaro P, Mureddu G F, Garofalo M, de Simone G, de Divitiis O
University of Naples, Italy.
Int J Clin Pharmacol Ther Toxicol. 1991 Dec;29(12):494-8.
In this study we used casual and 24-h blood pressure (BP) monitoring and Doppler echocardiographic data to investigate the antihypertensive and hemodynamic effects of isradipine 5 mg in the new slow-release oral (SRO) formulation administered once daily for 12 weeks to 10 patients with mild to moderate hypertension. The antihypertensive action of SR isradipine was revealed by the normalized values of casual BP in 60 patients and by the significant reduction of 24-h BP variability as assessed by mean standard variation, coefficient of variation and the percent incidence of abnormal levels of both systolic and diastolic BP during 24 h (p less than .001). The echocardiographic data showed some beneficial hemodynamic effects (improvement of systolic and diastolic indices) without significant variation of left ventricular structure. The drug was well tolerated, with a low incidence of side effects. In conclusion, SR isradipine can be considered a safe and effective first-choice drug for the treatment of mild to moderate hypertension.
在本研究中，我们使用偶测血压和24小时血压（BP）监测以及多普勒超声心动图数据，来研究新型缓释口服（SRO）制剂中5毫克伊拉地平每日给药一次，连续12周对10例轻度至中度高血压患者的降压及血流动力学效应。通过60例患者偶测血压的标准化值以及通过平均标准差、变异系数和24小时内收缩压和舒张压异常水平的发生率评估的24小时血压变异性的显著降低，揭示了缓释伊拉地平的降压作用（p小于0.001）。超声心动图数据显示出一些有益的血流动力学效应（收缩期和舒张期指标的改善），而左心室结构无明显变化。该药物耐受性良好，副作用发生率低。总之，缓释伊拉地平可被视为治疗轻度至中度高血压的安全有效的首选药物。
